Mitoxantrone (N) vs. 5-fluorouracil/epirubicin/cyclophosphamide (FEC) as first line therapy in high-risk metastatic breast cancer

被引：0

作者：

vonMinckwitz, G

Heidemann, E

Souchon, R

Samonigg, H

Hirschmann, WD

Bodenstein, H

Schindler, A

Schulze, M

Clemens, H

Konig, M

Scharl, A

Fischer, JT

Kaufmann, M

机构：

[1] UNIV FRANKFURT,FRAUENKLIN,D-6000 FRANKFURT,GERMANY

[2] DIAKONISSENKRANKENHAUS STUTTGART,STUTTGART,GERMANY

[3] KH HAGEN,HAGEN,GERMANY

[4] UNIV KLIN GRAZ,GRAZ,AUSTRIA

[5] STADT KLINIKEN KASSEL,KASSEL,GERMANY

[6] KH MINDEN,MINDEN,GERMANY

[7] UNIV ESSEN GESAMTHSCH,FRAUENKLIN,ESSEN,GERMANY

[8] KH ZITTAU,ZITTAU,GERMANY

[9] UNIV TUBINGEN,KINDERKLIN,D-7400 TUBINGEN,GERMANY

[10] UNIV TUBINGEN,MED KLIN,D-7400 TUBINGEN,GERMANY

[11] UNIV COLOGNE,FRAUENKLIN,COLOGNE,GERMANY

[12] STADT KLINIKEN KARLSRUHE,KARLSRUHE,GERMANY

来源：

EUROPEAN JOURNAL OF CANCER | 1997年 / 33卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：646 / 646

页数：2

共 50 条

[1] 5-FLUOROURACIL, ADRIAMYCIN, CYCLOPHOSPHAMIDE (FAC) VS 5-FLUOROURACIL, EPIRUBICIN, CYCLOPHOSPHAMIDE (FEC) IN METASTATIC BREAST-CANCER
LOPEZ, M
PAPALDO, P
DILAURO, L
VICI, P
CARPANO, S
CONTI, EMS
ONCOLOGY, 1989, 46 (01) : 1 - 5
[2] Individually tailored toxicity-based 5-fluorouracil, epirubicin and cyclophosphamide (FEC) therapy of metastatic breast cancer
Lindman, Henrik
Astrom, Gunnar
Ahlgren, Johan
Villman, Kenneth
Blomqvist, Carl
Nygren, Peter
Bergh, Jonas
ACTA ONCOLOGICA, 2007, 46 (02) : 165 - 171
[3] 5-FLUOROURACIL, EPIRUBICIN AND CYCLOPHOSPHAMIDE (FEC COMBINATION) IN ADVANCED BREAST-CANCER
ZAMAGNI, C
MARTONI, A
ERCOLINO, L
BARONI, M
TANNEBERGER, S
PANNUTI, F
JOURNAL OF CHEMOTHERAPY, 1991, 3 (02) : 126 - 129
[4] First-line chemotherapy for metastatic breast cancer in high-risk patients -: Greater therapeutic effect with mitoxantron monotherapy than with combination therapy with 5-fluorouracil, epirubicin and cyclophosphamide
Heidemann, E
Stoeger, H
Souchon, R
Hirschmann, WD
Bodenstein, H
Oberhoff, C
Fischer, JT
Schulze, M
Clemens, M
Andreesen, R
Mahlke, M
König, M
Scharl, A
Gruener, A
Fehnle, K
Kaufmann, M
ONKOLOGIE, 2000, 23 (03): : 2 - 4
[5] First-line monochemotherapy with mitoxantrone versus combination with fluorouracil, epirubicin and cyclophosphamide in high-risk metastatic breast cancer:: A prospective randomized multicenter clinical trial
Heidemann, E
Souchon, R
Stöger, H
Hirschmann, WD
Bodenstein, H
Oberhoff, C
Fischer, JT
Schulze, M
Clemens, M
Mahlke, M
König, M
Scharl, A
Fehnle, K
Kaufmann, M
ONKOLOGIE, 2000, 23 (01): : 54 - 59
[6] Serum bone markers in breast cancer patients during 5-fluorouracil, epirubicin and cyclophosphamide (FEC) therapy
Kailajärvi, MEH
Salminen, EK
Paija, OMM
Virtanen, AM
Leino, AE
Irjala, KA
ANTICANCER RESEARCH, 2004, 24 (2C) : 1271 - 1274
[7] COMBINATION THERAPY OF METASTASIZED BREAST-CANCER WITH MITOXANTRONE, CYCLOPHOSPHAMIDE AND 5-FLUOROURACIL
MERKLE, E
FUCHS, U
BAHR, I
WIRTZ, PM
TULUSAN, AH
LANG, N
TUMORDIAGNOSTIK & THERAPIE, 1990, 11 (04) : 162 - 166
[8] Epirubicin Followed by Cyclophosphamide, Methotrexate and 5-Fluorouracil versus Paclitaxel Followed by Epirubicin and Vinorelbine in Patients with High-Risk Operable Breast Cancer
Boccardo, Francesco
Amadori, Dino
Guglielmini, Pamela
Sismondi, Piero
Farris, Antonio
Agostara, Biagio
Gambi, Angelo
Catalano, Giuseppina
Faedi, Marina
Rubagotti, Alessandra
ONCOLOGY, 2010, 78 (3-4) : 274 - 281
[9] COMBINATION CHEMOTHERAPY WITH CYCLOPHOSPHAMIDE, MITOXANTRONE AND 5-FLUOROURACIL IN PATIENTS WITH METASTATIC BREAST-CANCER
YAP, HY
ESPARZA, L
BLUMENSCHEIN, GR
HORTOBAGYI, GN
BODEY, GP
CANCER TREATMENT REVIEWS, 1983, 10 : 53 - 55
[10] MITOXANTRONE, CYCLOPHOSPHAMIDE, AND 5-FLUOROURACIL IN THE TREATMENT OF HORMONALLY UNRESPONSIVE METASTATIC BREAST-CANCER
HOLMES, FA
YAP, HY
ESPARZA, L
BUZDAR, AU
HORTOBAGYI, GN
BLUMENSCHEIN, GR
SEMINARS IN ONCOLOGY, 1984, 11 (03) : 28 - 31

← 1 2 3 4 5 →